Breast cancer

Systemic therapy for early stage TNBC

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.


Educational Objective: Gain insight into the selection of systemic therapies in patients with early stage TNBC, with a focus on the neoadjuvant and post-neoadjuvant setting.
Specialty: Medical oncology, Clinical oncology
Target Audience: CME (basic, intermediate), Residents (senior)
Latest update: January 2024

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Chemotherapy has been the mainstay of treatment and shifted from the adjuvant to neoadjuvant setting in early stage disease. This topic will highlight the use of newer treatments, including immunotherapy and targeted therapy, in both the neoadjuvant and adjuvant settings to treat TNBC.

Regulatory approval status of non-chemotherapy agents in the early stage TNBC setting (status 3 January 2024)

This educational platform includes case challenges with treatment options that may not be indicated for this use in your country. Please refer to your local prescribing information.